These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1268 related articles for article (PubMed ID: 31065941)

  • 1. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
    Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
    CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
    De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
    CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.
    Corponi F; Fabbri C; Bitter I; Montgomery S; Vieta E; Kasper S; Pallanti S; Serretti A
    Eur Neuropsychopharmacol; 2019 Sep; 29(9):971-985. PubMed ID: 31255396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.
    Lao KS; He Y; Wong IC; Besag FM; Chan EW
    CNS Drugs; 2016 Nov; 30(11):1043-1054. PubMed ID: 27550371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Metabolic Characteristics of Newer Second Generation Antipsychotics: Brexpiprazole, Lurasidone, Asenapine, Cariprazine, and Iloperidone With Olanzapine as a Comparator.
    Greger J; Aladeen T; Lewandowski E; Wojcik R; Westphal E; Rainka M; Capote H
    J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):5-12. PubMed ID: 33177350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.
    Citrome L
    CNS Drugs; 2013 Nov; 27(11):879-911. PubMed ID: 24062193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
    Citrome L
    Postgrad Med; 2011 Mar; 123(2):153-62. PubMed ID: 21474903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.
    De Hert M; Sermon J; Geerts P; Vansteelandt K; Peuskens J; Detraux J
    CNS Drugs; 2015 Aug; 29(8):637-58. PubMed ID: 26293744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis.
    Thomas JE; Caballero J; Harrington CA
    Curr Neuropharmacol; 2015; 13(5):681-91. PubMed ID: 26467415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder: Absolute Risk Increase and Number Needed to Harm.
    Citrome L
    J Clin Psychopharmacol; 2017 Apr; 37(2):138-147. PubMed ID: 28141623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Cariprazine in Acute Management of Psychiatric Disorders: a Meta-Analysis of Randomized Controlled Trials.
    Cooper H; Mishriky R; Reyad AA
    Psychiatr Danub; 2020; 32(1):36-45. PubMed ID: 32303028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Akathisia and Newer Second-Generation Antipsychotic Drugs: A Review of Current Evidence.
    Chow CL; Kadouh NK; Bostwick JR; VandenBerg AM
    Pharmacotherapy; 2020 Jun; 40(6):565-574. PubMed ID: 32342999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment.
    Broder MS; Greene M; Yan T; Chang E; Hartry A; Yermilov I
    Clin Ther; 2019 Feb; 41(2):221-232. PubMed ID: 30616973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2019 Oct; 73(10):e13397. PubMed ID: 31355510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review of the Pharmacological and Clinical Profile of Newer Atypical Antipsychotics as Treatments for Bipolar Disorder: Considerations for Use in Older Patients.
    Vasudev A; Chaudhari S; Sethi R; Fu R; Sandieson RM; Forester BP
    Drugs Aging; 2018 Oct; 35(10):887-895. PubMed ID: 30187288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Black Book of Psychotropic Dosing and Monitoring.
    DeBattista C; Schatzberg AF
    Psychopharmacol Bull; 2024 Jul; 54(3):8-59. PubMed ID: 38993656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.
    Arango C; Ng-Mak D; Finn E; Byrne A; Loebel A
    Eur Child Adolesc Psychiatry; 2020 Sep; 29(9):1195-1205. PubMed ID: 31758359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.